This startup uses AI to analyze previously unexamined regions of the human genome, translating complex genetic data into actionable insights. Their technology helps healthcare providers enhance patient care and accelerates drug discovery by revealing new genetic associations.
Funding
$1.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Analyzing the entire human genome, including non-coding regions and structural variations, presents significant challenges due to noisy data and the complexity of identifying pathogenic variants. Current short-read sequencing methods struggle with accurately detecting structural variants, while long-read sequencing remains expensive, limiting comprehensive genomic analysis. This incomplete analysis hinders the discovery of novel genetic associations and slows down both drug discovery and precision medicine efforts.
Solution
Lucid Genomics offers an AI-powered platform that enables comprehensive analysis of the whole genome, covering both coding and non-coding DNA, to identify and prioritize causative pathogenic mutations. The platform leverages advanced AI algorithms to reduce false positives in variant detection by up to 87%, even with short-read sequencing data. By integrating multi-omics data, including epigenetic modifications, gene expression, and 3D genome interactions, Lucid Genomics provides a deeper understanding of genetic variations and their impact. The platform supports various sequencing technologies and offers integrated visualization tools to facilitate hypothesis generation and collaboration.
Target Audience
Lucid Genomics targets researchers, clinicians, and pharmaceutical companies involved in drug discovery, precision medicine, and genomic research, who require comprehensive and accurate analysis of whole genome sequencing data.
Features
- AI-driven variant detection that reduces false positives by up to 87% for structural variants (DEL, DUP, INS, INV) in short-read sequencing data.
- Disease-agnostic AI prioritization method (TADA) that ranks known pathogenic variants with high accuracy.
- Multi-omics data integration, combining epigenetic modifications, gene expression, and 3D genome interactions for comprehensive analysis.
- Fast, large-scale cohort analysis, enabling the analysis of thousands of genes across hundreds of samples.
- Integrated visualization tools, including automated IGV-like visualizations, for streamlined analysis and hypothesis generation.
- Collaboration features for easy sharing and discussion of findings among team members.
- Support for various sequencing technologies, including short-reads, long-reads, and linked-reads.
- End-to-end bioinformatic solutions, from FastQ to VCF, simplifying the workflow.